A detailed history of Deutsche Bank Ag\ transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 162,858 shares of COGT stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,858
Previous 238,440 31.7%
Holding current value
$1.33 Million
Previous $2.01 Million 12.54%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$8.24 - $11.48 $622,795 - $867,681
-75,582 Reduced 31.7%
162,858 $1.76 Million
Q2 2024

Aug 14, 2024

SELL
$6.01 - $9.04 $2,920 - $4,393
-486 Reduced 0.2%
238,440 $2.01 Million
Q1 2024

May 15, 2024

BUY
$4.38 - $9.02 $882,530 - $1.82 Million
201,491 Added 538.24%
238,926 $1.61 Million
Q4 2023

Feb 14, 2024

SELL
$4.06 - $10.08 $2,431 - $6,037
-599 Reduced 1.57%
37,435 $220,000
Q3 2023

Nov 09, 2023

BUY
$9.69 - $13.34 $88,237 - $121,474
9,106 Added 31.48%
38,034 $370,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.24 $147,464 - $198,216
-14,971 Reduced 34.1%
28,928 $342,000
Q1 2023

May 15, 2023

BUY
$10.04 - $15.5 $86,625 - $133,734
8,628 Added 24.46%
43,899 $473,000
Q4 2022

Feb 13, 2023

BUY
$10.65 - $14.84 $90,056 - $125,487
8,456 Added 31.53%
35,271 $407,000
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $53,757 - $97,267
5,725 Added 27.15%
26,815 $400,000
Q2 2022

Aug 11, 2022

BUY
$3.92 - $9.73 $3,578 - $8,883
913 Added 4.52%
21,090 $190,000
Q1 2022

May 13, 2022

SELL
$5.31 - $8.7 $12,733 - $20,862
-2,398 Reduced 10.62%
20,177 $151,000
Q4 2021

Feb 11, 2022

BUY
$7.51 - $10.81 $9,027 - $12,993
1,202 Added 5.62%
22,575 $194,000
Q3 2021

Nov 04, 2021

SELL
$5.99 - $9.14 $4,115 - $6,279
-687 Reduced 3.11%
21,373 $180,000
Q2 2021

Aug 11, 2021

BUY
$7.82 - $9.3 $172,509 - $205,158
22,060 New
22,060 $179,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $539M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.